ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date
  • Abstract Number: 2534

    Radiographic Remission in Patients with Seropositive RA at Ten Years after Diagnosis, Treated in a Real Life Setting
  • Abstract Number: 2535

    Effect of Methotrexate in the Presence of Drug and the Appearance of Antibodies Against Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
  • Abstract Number: 2536

    The Performance of a Single Centre Interventional Clinic in Early Rheumatoid Arthritis
  • Abstract Number: 2537

    High Retention Rates and Clinical Efficacy of Tocilizumab As First-Line Biologic Treatment in Patients with Rheumatoid Arthritis
  • Abstract Number: 2538

    Comparison of Intravenous Versus Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis in a Routine Clinical Care Setting: A Preliminary, Time to Response Analysis
  • Abstract Number: 2539

    Analysis of Joints Susceptible to Rheumatoid Arthritis (RA) and Their Recovery Sequence Based on DAS28 and Physical Function Based on HAQ with Smart System of Disease Management (SSDM) in China:a Prospective Cohort Study
  • Abstract Number: 2540

    The Longitudinal Impact of Biologic Use on Disability within a RA Registry
  • Abstract Number: 2541

    Glucocorticoid Use and Low Thoracic Bone Mineral Density Are Predictors for Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of the Tomorrow Study
  • Abstract Number: 2542

    Reducing the Dosage of Glucocorticoid to Zero Might Decrease Risk of Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of the Tomorrow Study
  • Abstract Number: 2543

    Impact of Concomitant Methotrexate Administration on the Risk of Infections Among Rheumatoid Arthritis Patients Treated with Anti-TNF in Real-World
  • Abstract Number: 2544

    Glucocorticoid Treatment for 12 Weeks in Early Rheumatoid Arthritis Is Related to an Increase in BMI
  • Abstract Number: 2545

    Physicians, but Not Patients, Agree That EULAR Good Response Indicates Remission after 12 Weeks Treatment of Early Rheumatoid Arthritis
  • Abstract Number: 2546

    Utilization of Biologic Therapy in Patients with Rheumatoid Arthritis and Cancer
  • Abstract Number: 2547

    Quantification of Adverse Glucocorticoid Effects on Skin in Rheumatoid Arthritis
  • Abstract Number: 2548

    Single 1g Infusion Vs Double 1g Infusion of Rituximab in Rheumatoid Arthritis in a Large Teaching Hospital: Potential Clinical Benefits and Financial Savings
  • « Previous Page
  • 1
  • …
  • 169
  • 170
  • 171
  • 172
  • 173
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology